Bullish
CLDX: Barzolvolimab shows strong, durable efficacy in urticaria with pivotal phase III data due Q4
Celldex Therapeutics' (CLDX) drug Barzolvolimab shows promising rapid, durable, and high complete response rates in urticaria, with Phase III data exp...